Literature DB >> 16682150

Prevertebral muscle involvement in nasopharyngeal carcinoma.

An-Chen Feng1, Mau-Ching Wu, Stella Y C Tsai, Kwan-Yee Chan, Skye H Cheng, Angel Wang, Shing-Su Chen, James J Jian, Shyuang-Der Terng, Andrew T Huang.   

Abstract

PURPOSE: The purpose of this study is to evaluate the prevalence and prognostic significance of prevertebral muscle involvement in patients with nasopharyngeal carcinoma (NPC). METHODS AND MATERIALS: Between July 1990 and December 2001, 521 newly diagnosed patients with NPC treated at Koo Foundation Sun Yat-Sen Cancer Center (KF-SYSCC) were examined with magnetic resonance imaging (MRI) for evidence of prevertebral muscle involvement before treatment. Patients were staged according to the 1997 American Joint Committee on Cancer staging classification of NPC based on the physical exams and MRI findings. All patients received radiotherapy with or without chemotherapy. The association between clinical prevertebral muscle involvement and posttreatment outcomes (overall survival, locoregional recurrence, and distant metastasis) were evaluated using Cox regression model to adjust for other prognostic factors.
RESULTS: Of 521 patients treated at KF-SYSCC, 181 (35%) patients were found to have prevertebral muscle involvement, one-third in those with Stage II/III tumors and two-thirds in those with Stage IV tumor. In multivariate analysis accounting for all previously known prognostic factors, prevertebral muscle invasion was associated with an increased risk for any recurrence (adjusted relative risk, 2.01; p<0.001), locoregional recurrence (adjusted relative risk, 2.69; p<0.001), and distant metastasis (adjusted relative risk, 2.25; p<0.001), and with a borderline significant increased risk for overall survival (adjusted relative risk, 1.44; p=0.10).
CONCLUSIONS: Prevertebral muscle involvement is an independent prognostic factor for NPC recurrence.

Entities:  

Mesh:

Year:  2006        PMID: 16682150     DOI: 10.1016/j.ijrobp.2006.02.012

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  6 in total

Review 1.  Resectability issues with head and neck cancer.

Authors:  D M Yousem; K Gad; R P Tufano
Journal:  AJNR Am J Neuroradiol       Date:  2006 Nov-Dec       Impact factor: 3.825

2.  Nasopharyngeal carcinoma: relationship between invasion of the prevertebral space and distant metastases.

Authors:  Qi-Yong Ai; Chen-Wen Hu; Kunwar S Bhatia; Darren M C Poon; Edwin P Hui; Frankie K F Mo; Benjamin King Hong Law; Macy Tong; Brigette B Ma; Anthony T C Chan; Ann D King
Journal:  Eur Arch Otorhinolaryngol       Date:  2017-11-29       Impact factor: 2.503

Review 3.  The evolution of nasopharyngeal carcinoma staging.

Authors:  Rui Guo; Yan-Ping Mao; Ling-Long Tang; Lei Chen; Ying Sun; Jun Ma
Journal:  Br J Radiol       Date:  2019-07-12       Impact factor: 3.039

4.  Analysis of the efficacy of intensity-modulated radiotherapy and two-dimensional conventional radiotherapy in nasopharyngeal carcinoma with involvement of the cervical spine.

Authors:  Hao Jiang; Gengming Wang; Hongwei Song; Hongbo Xu; Yajun Zhang; Yufu Zhou; Hanfei Cai; Shimiao Duan
Journal:  Oncol Lett       Date:  2015-09-03       Impact factor: 2.967

5.  Proposal for the 8th edition of the AJCC/UICC staging system for nasopharyngeal cancer in the era of intensity-modulated radiotherapy.

Authors:  Jian Ji Pan; Wai Tong Ng; Jing Feng Zong; Lucy L K Chan; Brian O'Sullivan; Shao Jun Lin; Henry C K Sze; Yun Bin Chen; Horace C W Choi; Qiao Juan Guo; Wai Kuen Kan; You Ping Xiao; Xu Wei; Quynh Thu Le; Christine M Glastonbury; A Dimitrios Colevas; Randal S Weber; Jatin P Shah; Anne W M Lee
Journal:  Cancer       Date:  2015-11-20       Impact factor: 6.860

6.  Prognostic value of classifying parapharyngeal extension in nasopharyngeal carcinoma based on magnetic resonance imaging.

Authors:  Guo-Yi Zhang; Ying Huang; Xue-Feng Hu; Xiang-Ping Chen; Tao Xu; Li-Zhi Liu; Wei-Hong Wei; Guo-Sen Huang; Miao-Miao Zhou; Ze-Li Huang; Yue-Jian Wang
Journal:  Biomed Res Int       Date:  2015-03-26       Impact factor: 3.411

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.